5,6-Dimethoxy-2-(Piperidin-4-ylmethyl)-2,3-Dihydro-1H-Inden-1-One

120014-30-4

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise thaπt is market-oriented and realizes industrial development through R&D innovatγion and technology transformation.

key word:

innovation Pharmaceutical

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-wi≤n

The company integrates multiple resources and strives ∞to build a large health industry finance platform company integrating pharmaceutical, intelligentδ medical, bio pharmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include" Foucault reaction, nitration reaction, sulfonation r"eaction, hydrogenation reaction, fluorination reaction, ch¥lorination reaction, bromination reaction, diazotization reaction, format reaction±, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed b×y Merck. In October 2006, Sitagliptin phosphate Januvia was approved by FDA as♥ the first DPP4 inhibitor for the treatment of type ⅱ diabetes me♠llitus. The characteristics of this drug are that it can stimulate insulin secretion w<hile reducing hunger without causing weight gain. Hypoglycemia and edema will notΩ occur, and it is suitable for diabetic patients with poor blood glucose control and frequent §hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orient♥ed and realizes industrial development through R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most φimportant products for the treatment of arthritis. It is well tolerated and has a low inciden¥ce of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antago¥nists. In clinical application, it has good therapeutic effect on atopic  asthma and other types of bronchial asthma, and the "market prospect is huge. In the major category of asthma drugs, leukotriene receptor antagonists÷ have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enter∞prise that is market-oriented and realizes industrial development through R&D innovation¶ and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It i"s the second drug approved by FDA for Alzheimer's disease in the Unit☆ed States. Its treatment reaches the target dose and has low to‌xic and side effects. It has been widely recognized by our medical c©ommunity, and good tolerance is its biggest advantage. In October 1999, Donepezil w×as launched in China under the trade name "Aricept", which is the m₹ain chemical drug against Alzheimer's disease. At present, CFDA has approved a number of domesγtic enterprises to produce donepezil preparations, the main dosage forms are ta blets, capsules, dispersive tablets, oral disintegrating tablεets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/σPfizer), a direct oral factor Xa inhibitor, was approved for€ use in the 27 EU member states. The world's first drug approved to prevent venous thromboemb‍olism (VTE) in adult patients undergoing elective hip or knee replacement. From June 2019± to June 2020, the annual sales of apixaban products overseaεs reached about $15.4 billion, with a year-on-year growth of n≈early 32%, and the API consumption reached about 23,960 kg, with a year-on-year growπth of about 28%. Compared with its main competitor, Rivaroxaban, the drug's annual overseas salesσ are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orien₹ted and realizes industrial development through R&D innovation and technolog←y transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzy§me. On December 29, 2004, it was approved by FDA for the treatment of refractory or relapsed acu te lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-or±iented and realizes industrial development through R&D innovation anβd technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other services♠, E-mail: 2880705932@qq.com
Submit

Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.